FY2028 Earnings Estimate for Iterum Therapeutics plc (NASDAQ:ITRM) Issued By HC Wainwright

Iterum Therapeutics plc (NASDAQ:ITRMFree Report) – Stock analysts at HC Wainwright issued their FY2028 EPS estimates for shares of Iterum Therapeutics in a note issued to investors on Wednesday, February 7th. HC Wainwright analyst E. Arce anticipates that the company will post earnings per share of $0.16 for the year. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Iterum Therapeutics’ current full-year earnings is ($2.93) per share.

Iterum Therapeutics Stock Performance

NASDAQ:ITRM opened at $1.59 on Thursday. Iterum Therapeutics has a 1 year low of $0.62 and a 1 year high of $2.50. The firm’s fifty day simple moving average is $1.80 and its 200 day simple moving average is $1.25. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 3.63. The firm has a market capitalization of $21.37 million, a PE ratio of -0.65 and a beta of 2.41.

Iterum Therapeutics (NASDAQ:ITRMGet Free Report) last posted its earnings results on Tuesday, November 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.61.

Insider Activity at Iterum Therapeutics

In other news, Director Michael W. Dunne bought 20,000 shares of the stock in a transaction that occurred on Wednesday, November 22nd. The shares were acquired at an average cost of $2.03 per share, for a total transaction of $40,600.00. Following the purchase, the director now owns 78,754 shares of the company’s stock, valued at approximately $159,870.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Michael W. Dunne purchased 25,000 shares of the firm’s stock in a transaction on Friday, December 22nd. The shares were bought at an average cost of $1.40 per share, for a total transaction of $35,000.00. Following the transaction, the director now directly owns 113,754 shares of the company’s stock, valued at approximately $159,255.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Michael W. Dunne purchased 20,000 shares of the firm’s stock in a transaction on Wednesday, November 22nd. The stock was bought at an average price of $2.03 per share, for a total transaction of $40,600.00. Following the completion of the transaction, the director now directly owns 78,754 shares in the company, valued at $159,870.62. The disclosure for this purchase can be found here. In the last three months, insiders have bought 55,000 shares of company stock worth $91,500. 5.40% of the stock is owned by insiders.

Institutional Trading of Iterum Therapeutics

Several institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. bought a new position in shares of Iterum Therapeutics in the second quarter worth about $61,000. Renaissance Technologies LLC grew its holdings in Iterum Therapeutics by 199.1% during the second quarter. Renaissance Technologies LLC now owns 323,300 shares of the company’s stock valued at $65,000 after purchasing an additional 215,200 shares during the period. Apollon Wealth Management LLC acquired a new position in Iterum Therapeutics during the second quarter valued at approximately $214,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Iterum Therapeutics in the third quarter valued at approximately $101,000. 3.39% of the stock is currently owned by institutional investors and hedge funds.

Iterum Therapeutics Company Profile

(Get Free Report)

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Recommended Stories

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.